AHA Conference 2024 - Outcomes of SELECT show that semaglutide treatment in obese or overweight patients with prior history of coronary artery bypass graft (CABG) surgery reduces the risk of cardiovascular events.

Dr Subodh Verma (University of Toronto, Toronto, CA) joins us onsite at AHA Conference to discuss the findings from SELECT (NCT03574597).

SELECT is a randomized, double-blind, placebo-controlled, phase 3 trial investigating the use of semaglutide compared to placebo in obese or overweight patients with prior history of cardiovascular disease, including those with prior history of CABG. 17,604 patients were enrolled in the trial and were followed up from randomization up to 240 weeks. The primary outcome measure was the number of participants with first occurrence of a composite outcome measure consisting of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death.

Interview Questions:
1.    What is the reasoning behind the trial and current research landscape for semaglutide treatment?
2.    What was the study design and patient population?
3.    What were the key findings?
4.    What are the take-home messages for practice?
5.    What further research is needed in this area?

Recorded on-site at AHA Conference in Chicago, 2024.

Editors: Yazmin Sadik, Jordan Rance.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.

Support: This is an independent interview produced by Radcliffe CVRM.